Atul vs BASF India vs Balaji Amines: Which Stock Should You Track
- September 23, 2026
- Posted by: Harsh Piplani
- Category: Market
Atul PE 22.42, mkt cap Rs 18,183 crore. BASF India PE 24.05, mkt cap Rs 15,466 crore. Balaji Amines PE 32.90, mkt cap Rs 6,932 crore.
Quick Answer
Atul vs BASF India vs Balaji Amines is a side-by-side comparison of three companies from the Specialty Chemicals space. On this comparison, Atul carries a market capitalisation of about Rs 18,183 crore against Rs 15,466 crore for BASF India and Rs 6,932 crore for Balaji Amines, with return on equity of 10.90%, 10.62% and 8.46% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.
Atul vs BASF India vs Balaji Amines starts with the core numbers most investors compare within the Specialty Chemicals segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.
All three names sit in the Specialty Chemicals bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.
Tap to Access Best Research Pieces on Univest
Atul, BASF India and Balaji Amines: Company Overview
Atul is a listed Indian company in the Specialty Chemicals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
BASF India is a listed Indian company in the Specialty Chemicals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Balaji Amines is a listed Indian company in the Specialty Chemicals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Atul vs BASF India vs Balaji Amines: Valuation and Profitability Snapshot
| Metric | Atul | BASF India | Balaji Amines |
|---|---|---|---|
| Market Cap (approx.) | Rs 18,183 crore | Rs 15,466 crore | Rs 6,932 crore |
| PE Ratio (TTM) | 22.42 | 24.05 | 32.90 |
| PB Ratio | 2.92 | 3.91 | 3.51 |
| Return on Equity (ROE) | 10.90% | 10.62% | 8.46% |
| EPS (TTM, Rs) | 275.44 | 148.55 | 65.04 |
| Dividend Yield | 0.49% | 0.70% | 0.51% |
| Debt to Equity | 0.03 | 0.03 | 0.07 |
| Book Value per Share (Rs) | 2113.31 | 914.27 | 610.00 |
Check the Univest Screener for Live Data
On valuation, Atul trades at a PE of 22.42 and a PB of 2.92, BASF India at a PE of 24.05 and a PB of 3.91, while Balaji Amines trades at a PE of 32.90 and a PB of 3.51. On return on equity, the three post 10.90%, 10.62% and 8.46% respectively, and on dividend yield they stand at 0.49%, 0.70% and 0.51%.
Atul vs BASF India vs Balaji Amines: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) |
|---|---|---|---|---|
| Atul | Rs 1,881.26 crore | Rs 253.93 crore | +25.1% | +6.9% |
| BASF India | Rs 4,846.51 crore | Rs 360.29 crore | +24.5% | +40.3% |
| Balaji Amines | Rs 461.45 crore | Rs 78.12 crore | +25.6% | +14.6% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY28, quarter ended June 2026), compared with the year-ago and preceding quarter where that data was available. A blank cell means the figure could not be independently verified in this pull and should be checked on the company’s own exchange filing before use.
Download the Univest iOS App or Univest Android App to track Atul, BASF India and Balaji Amines live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three specialty chemicals names should track quarter-on-quarter revenue and margin trends, management commentary on order books or demand, and any sector-specific regulatory or input-cost developments, since a single-quarter snapshot can shift quickly.
Conclusion
Atul vs BASF India vs Balaji Amines highlights how differently three companies in the same specialty chemicals segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Atul vs BASF India vs Balaji Amines
What is the market cap difference between Atul, BASF India and Balaji Amines?
Ans. As of September 2026, Atul has a market cap of approximately Rs 18,183 crore, BASF India is at approximately Rs 15,466 crore, and Balaji Amines is at approximately Rs 6,932 crore.
Which of the three has the highest PE ratio?
Ans. Among Atul, BASF India and Balaji Amines, the PE ratios stand at 22.42, 24.05 and 32.90 respectively as of September 2026.
Which of the three has the highest ROE?
Ans. Atul, BASF India and Balaji Amines post ROE of 10.90%, 10.62% and 8.46% respectively as of September 2026.
Which of these three stocks pays the highest dividend yield?
Ans. Atul, BASF India and Balaji Amines carry dividend yields of 0.49%, 0.70% and 0.51% respectively.
What is the debt to equity ratio for Atul, BASF India and Balaji Amines?
Ans. Atul carries a debt to equity of 0.03, BASF India of 0.03, and Balaji Amines of 0.07.
Which of the three trades at the highest price to book value?
Ans. Atul, BASF India and Balaji Amines trade at price to book ratios of 2.92, 3.91 and 3.51 respectively.
Is one of Atul, BASF India or Balaji Amines better than the others?
Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.
